Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in January 2022
14 Dicembre 2021 - 07:00AM
Business Wire
POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage
biopharmaceutical company developing innovative treatments for
chronic serious diseases with metabolic pathophysiology, including
non-alcoholic steatohepatitis (NASH) and rare disorders, today
announced its participation at upcoming investor and scientific
conferences in January 2022.
Date: January 6-8, 2022 Park City, Utah,
USA David Moller, Executive Vice President, Chief Scientific
Officer (CSO), will present a poster entitled: “Preclinical and
Early Clinical Characterization of PXL065 - Deuterium-Stabilized
(R)-Pioglitazone – a Potential Novel Oral Therapy for NASH”
Date: January 6-11, 2022 Thomas Kuhn,
Chief Executive Officer (CEO), and Anne Renevot, Chief Financial
Officer, will be available for one-on-one virtual meetings.
- H.C. Wainwright BioConnect (virtual)
Date: January 10-13, 2022 Thomas Kuhn,
CEO, will present, and Poxel management team members will be
available for one-on-one virtual meetings.
- Degroof Petercam’s Healthcare Conference 2022
(virtual)
Date: January 25, 2022 Thomas Kuhn,
CEO, will present, and Poxel management team members will be
available for one-on-one virtual meetings.
About Poxel SA
Poxel is a clinical stage biopharmaceutical company
developing innovative treatments for chronic serious diseases
with metabolic pathophysiology, including non-alcoholic
steatohepatitis (NASH) and rare disorders. Poxel has clinical
and earlier-stage programs from its adenosine
monophosphate-activated protein kinase (AMPK) activator and
deuterated TZD platforms targeting chronic and rare metabolic
diseases. For the treatment of NASH, PXL065
(deuterium-stabilized R-pioglitazone) is in a streamlined Phase 2
trial (DESTINY-1). PXL770, a first-in-class direct AMPK
activator, has successfully completed a Phase 2a proof-of-concept
trial for the treatment of NASH, which met its objectives. For the
rare inherited metabolic disorder, adrenoleukodystrophy (ALD), the
company intends to initiate Phase 2a proof of concept studies with
PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN).
TWYMEEG® (Imeglimin), Poxel’s first-in-class lead product
that targets mitochondrial dysfunction, has been approved and
launched for the treatment of type 2 diabetes in Japan. Poxel
expects to receive sales-based payments and royalties from Sumitomo
Dainippon Pharma. Poxel has a strategic partnership with Sumitomo
Dainippon Pharma for Imeglimin in Japan, China, South Korea, Taiwan
and nine other Southeast Asian countries. The Company intends to
generate further growth through strategic partnerships and pipeline
development. Listed on Euronext Paris, Poxel is headquartered in
Lyon, France, and has subsidiaries in Boston, MA, and Tokyo,
Japan.
For more information, please visit: www.poxelpharma.com
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211213006044/en/
Poxel SA
Aurélie Bozza Investor Relations & Communication Director
aurelie.bozza@poxelpharma.com +33 6 99 81 08 36
Elizabeth Woo Senior Vice President, Investor Relations &
Communication elizabeth.woo@poxelpharma.com
Investor relations / Media NewCap Emmanuel Huynh or
Arthur Rouillé poxel@newcap.eu +33 1 44 71 94 94
Grafico Azioni Poxel (EU:POXEL)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Poxel (EU:POXEL)
Storico
Da Mar 2023 a Mar 2024